1 Prednisone in COPD exacerbation requiring ventilatory support: An open‐label randomised evaluation Fekri Abroug (MD) 1,3 , Lamia Ouanes‐Besbes (MD) 1,3 , Mohamed Fkih‐Hassen (MD) 2,3 , Islem Ouanes (MD) 1,3 , Samia Ayed (MD) 2,3 , Fahmi Dachraoui (MD) 1,3 , Laurent Brochard 4 ,Souheil ElAtrous (MD) 2,3 . 1 Intensive Care Unit. CHU Fattouma Bourguiba. Monastir. University of Monastir. Tunisia 2 Intensive Care Unit. CHU Tahar Sfar. Mahdia. University of Monastir. Tunisia 3 Laboratoire de Recherche LR12SP15 “Recherche cardiopulmonaire en médecine intensive et Toxicologie » 4 ICU Division, Department of Anesthesiology, Pharmacology and Intensive Care, Geneva University Hospital. University of Geneva, Switzerland. Correspondence : Prof Fekri Abroug Intensive Care Unit CHU Fattouma Bourguiba 5000 Monastir. Tunisia [email protected]Running head : Systemic steroids in acute exacerbation of COPD Study message: In COPD exacerbation requiring ventilatory support, Prednisone has no impact on ICU mortality or related patient‐ centred outcomes. This study is registered with clinicaltrials.gov number: NCT01353235 Author contribution: FA designed the study, contributed to analysis, and wrote the first draft of the paper with input from all other authors. LOB, LB and SE participated in study conception and design, data analysis, and finalising the report. MFH, SA, IO and FD participated in acquisition of data and drafting of the report. All authors revised the report and have seen and approved the final report. . Published on June 21, 2013 as doi: 10.1183/09031936.00002913 ERJ Express Copyright 2013 by the European Respiratory Society.
21
Embed
Prednisone in COPD exacerbation requiring ventilatory support: an open-label randomised evaluation
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Prednisone in COPD exacerbation requiring ventilatory support: An open‐label randomised evaluation
Fekri Abroug (MD)1,3, Lamia Ouanes‐Besbes (MD)1,3, Mohamed Fkih‐Hassen (MD)2,3, Islem Ouanes (MD)1,3, Samia Ayed (MD)2,3, Fahmi Dachraoui (MD)1,3, Laurent Brochard 4,Souheil ElAtrous (MD)2,3. 1 Intensive Care Unit. CHU Fattouma Bourguiba. Monastir. University of Monastir. Tunisia 2 Intensive Care Unit. CHU Tahar Sfar. Mahdia. University of Monastir. Tunisia 3 Laboratoire de Recherche LR12SP15 “Recherche cardiopulmonaire en médecine intensive et Toxicologie » 4 ICU Division, Department of Anesthesiology, Pharmacology and Intensive Care, Geneva University Hospital. University of Geneva, Switzerland. Correspondence : Prof Fekri Abroug Intensive Care Unit CHU Fattouma Bourguiba 5000 Monastir. Tunisia [email protected] Running head : Systemic steroids in acute exacerbation of COPD
Study message: In COPD exacerbation requiring ventilatory support, Prednisone has no impact on ICU mortality or related patient‐ centred outcomes.
This study is registered with clinicaltrials.gov number: NCT01353235
Author contribution:
FA designed the study, contributed to analysis, and wrote the first draft of the paper with
input from all other authors. LOB, LB and SE participated in study conception and design,
data analysis, and finalising the report. MFH, SA, IO and FD participated in acquisition of data
and drafting of the report. All authors revised the report and have seen and approved the
final report.
. Published on June 21, 2013 as doi: 10.1183/09031936.00002913ERJ Express
Copyright 2013 by the European Respiratory Society.
2
Abstract :
Background: Recommendations of systemic steroids in COPD exacerbation rely on trials that
excluded patients requiring ventilatory support.
Methods: in an open‐label, randomised evaluation of oral prednisone administration, 217
patients with acute COPD exacerbation requiring ventilatory support were randomised (with
stratification on the type of ventilation) to usual care (n=106), or to receive a daily dose of
prednisone (1mg/kg) for up to 10 days (n=111).
Results: There was no difference regarding the primary end‐point, in‐ICU mortality: 17
deaths (15.3%) vs 15 deaths (14%), in steroid treated and in control groups, respectively
(Relative risk: 1.08, 95%CI: 0.6‐2.05). Analysis according to ventilation modalities showed
similar mortality rates. NIV failed in 15.7% and 12.7% (RR: 1.25, 95%CI: 0.56‐2.8, p=0.59),
respectively. Both study groups had similar median mechanical ventilation duration, and ICU
length of stay: 6 (3‐12) days vs 6 (3.8‐12), and 9 (6‐14) vs 8 (6‐14), respectively.
Hyperglycaemic episodes requiring initiation or alteration of current insulin doses occurred
in 55 patients (49.5%) vs 35 patients (33%) in prednisone and control groups, respectively
(RR: 1.5, 95%CI: 1.08‐2.08; p=0.015).
Conclusions: Prednisone did not improve ICU mortality or patient‐centred outcomes in the
selected subgroup of COPD patients with severe exacerbation. It significantly increased the
ICU length of stay (days) 9 (6‐14) 8 (6‐14) 0.88 Safety endpoint Hyperglycemic episodes requiring initiation or alteration of insulin therapy
55/111 (49.5%) 35/106 (33%) 1.5 (1.08‐2.08) 0.015
Définition of abbreviations: ICU = intensive care unit, NIV= non invasive ventilation
17
18
Figure 1: Flow chart
Screened for eligibility
518
Excluded : 301
160 Steroid treatment
74 Pneumonia
32 Pulmonary embolism
19 Pneumothorax
16 Refused consent
Prednisone Group
111
Control Group
106
Non Invasive Ventilation
84
Conventional mechanical
ventilation
27
Conventional mechanical
ventilation
30
Non Invasive Ventilation
80
Included in the study
217
19
References:
1. Global Strategy for the Diagnosis MaPoC. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Available from: http://wwwgoldcopdorg/ 2011. 2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker‐Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Abdulhak AB, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FGR, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez‐Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo J‐P, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KMV, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez‐Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui‐Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh P‐H, Yip P, Zabetian A, Zheng Z‐J, Lopez AD, Murray CJL. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet 2012: 380(9859): 2095‐2128. 3. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007: 370(9589): 786‐796. 4. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2004: 23(6): 932‐946. 5. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska‐Mogilnicka E. International variation in the prevalence of COPD (the BOLD Study): a population‐based prevalence study. Lancet 2007: 370(9589): 741‐750. 6. Connors AF, Jr., Dawson NV, Thomas C, Harrell FE, Jr., Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996: 154(4 Pt 1): 959‐967. 7. Pinto‐Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6‐min walk distance: change over time and value as a predictor of survival in severe COPD. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2004: 23(1): 28‐33. 8. Strassels SA, Smith DH, Sullivan SD, Mahajan PS. The costs of treating COPD in the United States. Chest 2001: 119(2): 344‐352.
9. Wedzicha JA, Wilkinson T. Impact of chronic obstructive pulmonary disease exacerbations on patients and payers. Proc Am Thorac Soc 2006: 3(3): 218‐221. 10. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002: 57(10): 847‐852. 11. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk DD, Balter M, Ford G, Gervais A, Goldstein R, Hodder R, Kaplan A, Keenan S, Lacasse Y, Maltais F, Road J, Rocker G, Sin D, Sinuff T, Voduc N. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease ‐ 2007 update. Can Respir J 2007: 14 Suppl B: 5B‐32B. 12. Perera WR, Hurst JR, Wilkinson TM, Sapsford RJ, Mullerova H, Donaldson GC, Wedzicha JA. Inflammatory changes, recovery and recurrence at COPD exacerbation. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2007: 29(3): 527‐534. 13. Fujimoto K, Yasuo M, Urushibata K, Hanaoka M, Koizumi T, Kubo K. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2005: 25(4): 640‐646. 14. Sayiner A, Aytemur ZA, Cirit M, Unsal I. Systemic glucocorticoids in severe exacerbations of COPD. Chest 2001: 119(3): 726‐730. 15. Pizzichini MM, Pizzichini E, Efthimiadis A, Chauhan AJ, Johnston SL, Hussack P, Mahony J, Dolovich J, Hargreave FE. Asthma and natural colds. Inflammatory indices in induced sputum: a feasibility study. Am J Respir Crit Care Med 1998: 158(4): 1178‐1184. 16. Wood‐Baker R, Walters J, Walters EH. Systemic corticosteroids in chronic obstructive pulmonary disease: an overview of Cochrane systematic reviews. Respir Med 2007: 101(3): 371‐377. 17. Walters JA, Gibson PG, Wood‐Baker R, Hannay M, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009(1): CD001288. 18. Cheng T, Gong Y, Guo Y, Cheng Q, Zhou M, Shi G, Wan H. Systemic corticosteroid for COPD exacerbations, whether the higher dose is better? A meta‐analysis of randomized controlled trials. The clinical respiratory journal 2012. 19. Chakrabarti B, Angus RM, Agarwal S, Lane S, Calverley PMA. Hyperglycaemia as a predictor of outcome during non‐invasive ventilation in decompensated COPD. Thorax 2009: 64(10): 857‐862. 20. Baker EH, Bell D. Blood glucose: of emerging importance in COPD exacerbations. Thorax 2009: 64(10): 830‐832. 21. Alia I, de la Cal MA, Esteban A, Abella A, Ferrer R, Molina FJ, Torres A, Gordo F, Elizalde JJ, de Pablo R, Huete A, Anzueto A. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Arch Intern Med 2011: 171(21): 1939‐1946. 22. Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo‐controlled trial. Lancet 2001: 358(9298): 2020‐2025. 23. Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, Rouleau M, Boukhana M, Martinot JB, Duroux P. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002: 165(5): 698‐703. 24. Bullard MJ, Liaw SJ, Tsai YH, Min HP. Early corticosteroid use in acute exacerbations of chronic airflow obstruction. Am J Emerg Med 1996: 14(2): 139‐143. 25. Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA 2010: 303(23): 2359‐2367.
21
26. de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double‐blind study. Chest 2007: 132(6): 1741‐1747. 27. Walters JA, Wang W, Morley C, Soltani A, Wood‐Baker R. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011(10): CD006897. 28. Ram FS, Picot J, Lightowler J, Wedzicha JA. Non‐invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2004(3): CD004104. 29. Saetta M, Di Stefano A, Maestrelli P, Turato G, Ruggieri MP, Roggeri A, Calcagni P, Mapp CE, Ciaccia A, Fabbri LM. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994: 150(6 Pt 1): 1646‐1652. 30. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, McCormick M, Haldar K, Kebadze T, Duvoix A, Lindblad K, Patel H, Rugman P, Dodson P, Jenkins M, Saunders M, Newbold P, Green RH, Venge P, Lomas DA, Barer MR, Johnston SL, Pavord ID, Brightling CE. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011: 184(6): 662‐671. 31. Pizzichini E, Pizzichini MM, Gibson P, Parameswaran K, Gleich GJ, Berman L, Dolovich J, Hargreave FE. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998: 158(5 Pt 1): 1511‐1517. 32. Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, Pavord ID. Sputum eosinophilia and short‐term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000: 356(9240): 1480‐1485. 33. Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, Monteiro W, Berry M, Parker D, Wardlaw AJ, Pavord ID. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2007: 29(5): 906‐913. 34. Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, Lomas DA, Barer MR, Johnston SL, Pavord ID, Brightling CE. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo‐controlled trial. Am J Respir Crit Care Med 2012: 186(1): 48‐55. 35. Maggiore SM, Richard JC, Abroug F, Diehl JL, Antonelli M, Sauder P, Mancebo J, Ferrer M, Lellouche F, Lecourt L, Beduneau G, Brochard L. A multicenter, randomized trial of noninvasive ventilation with helium‐oxygen mixture in exacerbations of chronic obstructive lung disease. Crit Care Med 2010: 38(1): 145‐151. 36. Esteban A, Ferguson ND, Meade MO, Frutos‐Vivar F, Apezteguia C, Brochard L, Raymondos K, Nin N, Hurtado J, Tomicic V, Gonzalez M, Elizalde J, Nightingale P, Abroug F, Pelosi P, Arabi Y, Moreno R, Jibaja M, D'Empaire G, Sandi F, Matamis D, Montanez AM, Anzueto A. Evolution of mechanical ventilation in response to clinical research. Am J Respir Crit Care Med 2008: 177(2): 170‐177. 37. Abroug F, Ouanes‐Besbes L, Nciri N, Sellami N, Addad F, Hamda KB, Amor AB, Najjar MF, Knani J. Association of left‐heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 2006: 174(9): 990‐996. 38. Scala R, Nava S, Conti G, Antonelli M, Naldi M, Archinucci I, Coniglio G, Hill NS. Noninvasive versus conventional ventilation to treat hypercapnic encephalopathy in chronic obstructive pulmonary disease. Intensive Care Med 2007: 33(12): 2101‐2108.